Glucagon-like peptide-1 drugs mimic a gut hormone that lowers blood sugar and curbs appetite. Learn how GLP-1 medications work, who they're for, and risks.
Glucagon-like peptide-1 drugs are prescription medications that copy a hormone your gut releases after you eat. They lower blood sugar, slow digestion, and reduce appetite, which is why the same drug class is used both for type 2 diabetes and for weight management. In the United States, this group includes semaglutide, liraglutide, dulaglutide, exenatide, and the dual-acting tirzepatide.
What Are Glucagon-Like Peptide-1 Drugs?
GLP-1 is a hormone your small intestine releases into the bloodstream within minutes of a meal. It belongs to a family of hormones called incretins, which help the body handle glucose after eating. The natural hormone is broken down quickly by an enzyme called DPP-4, so it only circulates for a minute or two.
Prescription GLP-1 drugs are engineered to resist that breakdown, so a single injection can keep the target active for a week instead of a couple of minutes. A common search question, what does glucagon-like peptide 1 do, has a fairly simple answer: the hormone signals the pancreas to release insulin when glucose rises, slows the rate at which the stomach empties, and dampens appetite signals in the brain.
These medications are not insulin, and they are not a cure for diabetes or obesity. They are long-term treatments that work best alongside diet, activity, and regular medical follow-up.
How GLP-1 Drugs Work in the Body
Every medication in this group acts as a glucagon-like peptide-1 receptor agonist. It binds to the same receptor the natural hormone targets, but it stays active for hours or days rather than minutes.
Once bound, the drug triggers several effects at once:
- Pancreas: insulin is released mainly when blood glucose is high, which lowers the risk of hypoglycemia when the drug is used on its own.
- Liver: glucagon output drops, so the liver releases less stored glucose.
- Stomach: food moves through more slowly, which extends fullness after meals.
- Brain: appetite and food cravings are reduced, and some people feel satisfied with smaller portions.
Tirzepatide works a little differently. It activates both the GLP-1 receptor and the GIP receptor, a second incretin pathway, which is one reason its trial results for weight loss are higher than those of single-agonist drugs.
How the Main GLP-1 Drugs Compare
| Generic name | Common brand names | Dosing | FDA-approved uses |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Weekly injection or daily oral tablet | Type 2 diabetes; chronic weight management; reduced cardiovascular risk |
| Liraglutide | Victoza, Saxenda | Daily injection | Type 2 diabetes; chronic weight management |
| Dulaglutide | Trulicity | Weekly injection | Type 2 diabetes; cardiovascular risk reduction |
| Exenatide | Byetta, Bydureon | Twice-daily or weekly injection | Type 2 diabetes |
| Tirzepatide | Mounjaro, Zepbound | Weekly injection | Type 2 diabetes; chronic weight management; obstructive sleep apnea with obesity |
Doses are started low and raised slowly over weeks. That step-up schedule is designed to let the digestive system adjust and to reduce nausea. Skipping doses or doubling up on your own can make side effects worse.
Benefits Beyond Blood Sugar Control
Large randomized trials have changed how clinicians think about the benefits of this drug class. The effects go well past glucose numbers.
- Weight loss: In the STEP program, semaglutide 2.4 mg produced roughly 15% average body weight loss over 68 weeks. In SURMOUNT-1, tirzepatide produced about 20% or more in adults without diabetes.
- Heart health: Semaglutide reduced major cardiovascular events by about 20% in adults with overweight or obesity and existing heart disease.
- Kidney protection: Semaglutide lowered the risk of kidney disease progression in people with type 2 diabetes and chronic kidney disease.
- Sleep apnea: Tirzepatide was approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
When people talk about glucagon-like peptide weight loss, these trial results are usually what they mean. The average numbers are real, but individual results vary widely, and weight often returns if the medication is stopped without other changes.
Side Effects, Safety, and Who Should Avoid Them
Nausea, vomiting, diarrhea, constipation, and stomach pain are the most common complaints. They are usually worst in the first weeks and after each dose increase.
Less common but more serious risks include pancreatitis, gallbladder disease, and severe gastroparesis. Federal regulators require a boxed warning about thyroid C-cell tumors seen in rodents, and these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
GLP-1 drugs are not recommended during pregnancy, and anyone planning to conceive should talk with their clinician first. Because these medicines slow stomach emptying, anesthesia guidelines now recommend holding them before some procedures.
GLP-1 medications are prescription treatments, not supplements, and a licensed clinician should decide whether one is appropriate for you.
GLP-1 Supplements, Foods, and Marketing Claims
Store shelves are full of products labeled as a glucagon-like peptide-1 supplement. No over-the-counter pill has been shown to raise GLP-1 levels enough to reproduce the weight loss seen with prescription drugs, and the FDA has warned about compounded versions sold without approved labeling.
No food contains GLP-1. Still, when people search for glucagon like peptide 1 foods, they usually land on advice that makes sense for blood sugar anyway: protein, fiber, vegetables, and fewer refined carbohydrates. Those habits support the hormone's natural release after meals, but they are not a substitute for medication.
Anyone considering a GLP-1 drug should review their full medication list, kidney function, and personal risk factors with a healthcare professional before starting.
Frequently Asked Questions
What are glucagon-like peptide-1 drugs used for?
GLP-1 drugs are FDA-approved to treat type 2 diabetes and, for some products, chronic weight management. Semaglutide and dulaglutide also carry approvals for reducing cardiovascular risk in certain patients, and tirzepatide is approved for obstructive sleep apnea in adults with obesity. They are prescribed alongside diet and exercise, not as a replacement for either.
How much weight can you lose on GLP-1 drugs?
In clinical trials, semaglutide 2.4 mg produced about 15% average body weight loss over 68 weeks, while tirzepatide reached roughly 20% or more in adults without diabetes. Results vary by person, dose, and how long the drug is taken. Weight often returns after the medication is stopped unless eating and activity habits change.
Are GLP-1 supplements the same as prescription GLP-1 drugs?
No. Over-the-counter products marketed as GLP-1 supplements are not FDA-approved to treat diabetes or obesity, and there is no reliable evidence they raise GLP-1 levels enough to produce meaningful weight loss. Prescription GLP-1 drugs contain a modified hormone that binds the receptor directly. Talk with a healthcare professional before substituting any supplement for a prescribed medication.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.